迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

未开盘 06-01 16:08:26

22.440

-0.340

-1.49%

最高23.360	最低22.220	成交量53.12万
今开22.740	昨收22.780	日振幅5.00%
总市值100.31亿	流通市值10.58亿	总股本4.47亿
成交额1,200万	换手率1.13%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":22.44,"timestamp":1780301306136,"preClose":22.78,"halted":0,"volume":531200,"delay":0,"changeRate":-0.014925373134328351,"floatShares":47130200,"shares":447000000,"eps":-2.815266894989694,"marketStatus":"未开盘","change":-0.34,"latestTime":"06-01 16:08:26","open":22.74,"high":23.36,"low":22.22,"amount":11997381,"amplitude":0.050044,"askPrice":22.46,"askSize":400,"bidPrice":22.4,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-2.700570836304929,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":0,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":22.78,"openAndCloseTimeList":[[1780277400000,1780286400000],[1780290000000,1780300800000]],"volumeRatio":0.7605520876835351,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":28.98,"timestamp":1780297200000,"preClose":30.4,"halted":0,"volume":9182600,"delay":0,"premium":"-33.16"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2640966924","title":"股市必读：迈威生物（688062）今年截至6月1日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640966924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640966924?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:38","pubTimestamp":1780335489,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，迈威生物报收于28.98元，下跌4.67%，换手率4.5%，成交量9.18万手，成交额2.74亿元。当日关注点来自交易信息汇总：迈威生物股价报28.98元，跌4.67%，已连续5日下跌，年内累计跌幅达25.41%。来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988329","title":"迈威生物-B(02493)建议选举唐春山、刘大涛、武海及华俊为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988329","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639988329?lang=zh_cn&edition=full","pubTime":"2026-05-31 19:57","pubTimestamp":1780228650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B 发布公告，第二届董事会于2023年4月27日由本公司2022年度股东会选举产生。经提名委员会资格审查和推荐，董事会建议选举唐春山先生、刘大涛博士、武海博士及华俊先生为执行董事，以及秦正余先生、周睿先生、李凡女士及王芳女士为独立非执行董事。选举职工代表董事无须经董事会或股东批准。胡会国先生、吴玉峰先生、许青博士及赵倩博士的卸任将于新董事在临时股东会上获选举后生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2639690317","title":"股市必读：迈威生物（688062）今年截至5月28日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639690317?lang=zh_cn&edition=full","pubTime":"2026-05-29 01:00","pubTimestamp":1779987637,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，迈威生物报收于30.59元，下跌4.73%，换手率3.82%，成交量7.79万手，成交额2.42亿元。当日关注点来自交易信息汇总：迈威生物股价连续3日下跌，当日主力资金净流出3344.38万元，占总成交额13.82%。交易信息汇总股价提醒5月28日迈威生物收盘报30.59元，跌4.73%，当日成交779.41万元。该股已连续3日下跌，当年累计跌幅21.26%。前10个交易日主力资金累计净流出5861.72万元，股价累计下跌13.61%；融资余额累计增加852.75万元，融券余量累计增加1.71万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","BK1161","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665342","title":"迈威生物跌4.73% 2022年上市募34.77亿国泰海通保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665342","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665342?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:17","pubTimestamp":1779956248,"startTime":"0","endTime":"0","summary":"中国经济网北京5月28日讯 迈威生物 今日收报30.59元，跌幅4.73%。　　迈威生物于2022年1月18日在上交所科创板上市，发行股份数量为9990.00万股，发行价格为34.80元/股，保荐机构为海通证券股份有限公司，保荐代表人为王永杰、陈新军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260528/32261286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1147","BK1564","02611","BK0188","BK0276","BK0184","601211","IPOS","BK0201","BK1161","BK0183","BK0028","BK0012","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637782093","title":"每周股票复盘：迈威生物（688062）9MW2821尿路上皮癌ORR达83.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637782093","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637782093?lang=zh_cn&edition=full","pubTime":"2026-05-24 01:48","pubTimestamp":1779558494,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，迈威生物报收于33.31元，较上周的34.34元下跌3.0%。本周，迈威生物5月22日盘中最高价报35.35元。公司公告汇总：9MW2821联合特瑞普利单抗在尿路上皮癌中整体人群ORR达83.0%。迈威生物自主研发的靶向Nectin-4 ADC药物9MW2821在2026年ASCO年会上以口头报告和壁报形式展示最新临床数据。9MW2821联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II期研究显示，整体人群客观缓解率为83.0%，经确认ORR为74.5%，完全缓解率12.8%，中位无进展生存期12.9个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637811361","title":"港股异动 | 迈威生物-B(02493)涨超6% 9MW2821最新临床数据将于2026年ASCO年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2637811361","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637811361?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:46","pubTimestamp":1779414404,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B涨超6%，截至发稿，涨5.22%，报25.8港元，成交额713.28万港元。据介绍，9MW2821为迈威生物靶向Nectin-4的首款定点偶联ADC新药，为公司利用ADC药物开发平台开发的创新品种，通过具有自主知识产权的偶联技术连接子及优化的ADC偶联工艺，实现抗体的定点修饰。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","02493","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637051332","title":"迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637051332?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:38","pubTimestamp":1779374294,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，迈威生物报收于33.48元，较前一交易日上涨1.09%，最新总市值为149.57亿元。该股当日开盘33.25元，最高35.07元，最低33.25元，成交额达3.61亿元，换手率为5.18%。近日，迈威生物发布自愿披露公告，宣布其自主研发的靶向Nectin-4 ADC药物9MW2821在2026年美国临床肿瘤学会年会上，将以口头报告和壁报形式展示最新临床数据。两项研究均未发现新的安全性信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389898","title":"迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389898","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389898?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:17","pubTimestamp":1779355058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司将在2026年5月29日-6 月2日于芝加哥举行的2026年美国临床肿瘤学会年会中，以口头报告形式公布靶向Nectin-4ADC创新药9MW2821 联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II 期临床研究数据，以壁报形式公布9MW2821联合特瑞普利单抗用于围手术期肌层浸润性膀胱癌的II期临床研究数据。9MW2821给药后，可与肿瘤细胞表面的Nectin-4结合并进入细胞，通过酶解作用，定向释放细胞毒素，从而实现对肿瘤的精准杀伤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","BK1161","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636121668","title":"迈威生物(688062.SH)：迈卫健®注射液增加适应症补充申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636121668","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636121668?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:27","pubTimestamp":1779265627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司全资子公司江苏泰康生物医药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，地舒单抗注射液增加实体肿瘤骨转移和多发性骨髓瘤适应症的补充申请获得国家药品监督管理局批准。公告显示，迈卫健主要竞争优势在于：1)作为国内第一梯队上市的安加维生物类似药，先发优势明显;2)展现了良好的治疗效果，被多个专家共识或治疗指南推荐。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02493","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409827","title":"5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409827?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488118,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日迈威生物涨5.80%，收盘报37.2元，换手率6.99%，成交量14.28万手，成交额5.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7862，较上一交易日下跌2.29%，近一年上涨13.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","163118","688062","000808.SH","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634472914","title":"港股异动 | 迈威生物-B(02493)午后涨近5% 创新药9MW5211临床试验申请获FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2634472914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634472914?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:57","pubTimestamp":1778479078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午后涨近5%，截至发稿，涨3.54%，报27.52港元，成交额3326.31万港元。消息面上，迈威生物宣布，其自主研发的抗体创新药9MW5211的临床试验申请正式获得美国食品药品监督管理局的许可，可针对炎症性肠病开展临床研究。其用于IBD和多发性硬化等多个适应症的临床试验申请已获国家药品监督管理局受理。9MW5211在其靶点上是全球首款进入临床阶段的候选药物。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159992","BK1161","BK0239","06978","02493","BK4588","BK4585","LABU","688062","BK1574","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432532","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432532","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432532?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:15","pubTimestamp":1778235339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，，9MW5211注射液用于炎症性肠病适应症的临床试验申请正式获得FDA许可，同时，其用于IBD和多发性硬化等多个适应症的临床试验申请已获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","BK4588","BK4585","02493","BK1161","BK0239","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195321528","title":"迈威生物-B发布2026年4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1195321528","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195321528?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:55","pubTimestamp":1778154938,"startTime":"0","endTime":"0","summary":"2026年5月7日，迈威生物-B（股票代码：02493）公布截至2026年4月30日止的证券变动月报。报告显示，公司H股为47,130,200股，A股为399,600,000股，注册股本合计人民币446,730,200元，各类股份在4月均未出现新增发行、回购或注销情形，股本总数维持不变。公司H股于2026年4月28日在香港联交所主板正式上市，上月底结存指上市日在册数据。\n公司公告称，已满足相关上市规则的公众持股量及其他合规要求。公司确认遵守香港联交所《上市规则》等适用法律法规的规定。公告由联席公司秘书王鹤飞女士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131510","title":"迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131510?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:09","pubTimestamp":1778076591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，为进一步优化债务结构，拓宽公司融资渠道，降低公司财务成本，根据公司战略发展规划及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过10亿元(含10亿元)的定向债务融资工具。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631702570","title":"迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631702570","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631702570?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:31","pubTimestamp":1777519860,"startTime":"0","endTime":"0","summary":"　　迈威生物-B最高涨超23%，触及31.46港元，创上市新高。截至发稿，涨7.22%，报27.32港元，成交额1.84亿港元。自成立以来，公司已推动4款产品获批上市，实现4款创新品种的对外授权。　　值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-30/doc-inhwfyeh7154434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK0239","IPOS","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631357717","title":"港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2631357717","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631357717?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:48","pubTimestamp":1777517308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B最高涨超23%，触及31.46港元创上市新高。值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54a3c0ad0e347d9e6f95c7a6e00c2a09","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","688062","BK1161","VXUS","BK4588","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184728154","title":"异动解读 | 迈威生物-B盘中大涨5.02%，一季报营收激增亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1184728154","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184728154?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:43","pubTimestamp":1777513394,"startTime":"0","endTime":"0","summary":"迈威生物-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，迈威生物近日发布了2026年第一季度财报，显示公司主营收入达到1.28亿元，同比大幅上升184.89%；同时，归母净利润为-2.42亿元，亏损同比收窄17.07%。此外，公司在TCE（T细胞衔接器）等创新药技术平台上的进展也受到关注，其基于空间位阻介导的双抗和三抗开发技术具有潜在优势，增强了投资者对公司研发管线未来潜力的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557899","title":"迈威生物（688062）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557899?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:52","pubTimestamp":1777503142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年一季报。根据财报显示，迈威生物营收上升亏损收窄。截至本报告期末，公司营业总收入1.28亿元，同比上升184.89%，归母净利润-2.42亿元，同比上升17.07%。本次财报公布的各项数据指标表现尚佳。持有迈威生物最多的基金为易方达医药生物股票A，目前规模为19.96亿元，最新净值0.8025，较上一交易日下跌0.86%，近一年上涨13.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184757618","title":"异动解读 | 迈威生物-B盘中大跌5.11%，一季度净亏损2.42亿元拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1184757618","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184757618?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:55","pubTimestamp":1777434903,"startTime":"0","endTime":"0","summary":"迈威生物-B（02493）今日盘中大跌5.11%，引发了市场的广泛关注。消息面上，公司于盘前发布了2026年第一季度财务报告。报告显示，公司期内归母净亏损为2.42亿元人民币，尽管亏损同比有所收窄，但整体业绩仍处于亏损状态。同时，公司资产负债率高达93.67%，较上一季度显著增加，凸显了其财务杠杆压力。这份不及市场预期的财报是导致股价承压下跌的主要原因。根据财报数据，迈威生物一季度营业收入为1.28亿元，同比增长显著。然而，高企的负债率以及持续的净亏损，削弱了投资者对公司短期盈利能力和财务健康状况的信心，从而在盘中引发了抛售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551636","title":"【特约大V】邓声兴：港股累跌两日有反弹之势，关键企稳26000","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551636","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631551636?lang=zh_cn&edition=full","pubTime":"2026-04-29 10:18","pubTimestamp":1777429087,"startTime":"0","endTime":"0","summary":"大市全日成交2623亿元。软银在日本股价跌幅达一成。港股累跌两日有反弹之势，关键企稳26000。值得留意的是，利润弹性并非单靠锂价，期内来自联营公司SQM的投资收益约4.28亿元，按年大增，加上财务费用由正转负至-1.51亿元，以及资产减值净转回约1.14亿元，多项因素共同放大盈利弹性，最终营业利润达37.36亿元。惟SQM与Codelco合作交易正式生效，天齐智利在当地诉讼终审败诉，公司表明将动态评估该长期股权投资的价值变动。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980185","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1227","BK4588","09696","SG9999014674.SGD","BK4585","BK1129","02493","01879","BK1500","01361","VXUS","BK1512","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0811},{"period":"1month","weight":-0.1356},{"period":"3month","weight":-0.1881},{"period":"ytd","weight":-0.1881}],"compareEarnings":[{"period":"1week","weight":-0.0081},{"period":"1month","weight":-0.0147},{"period":"3month","weight":-0.0144},{"period":"6month","weight":-0.0141},{"period":"1year","weight":0.0905},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}